Recruiting
Phase 1
Phase 2

Vinorelbine & Sorafenib

Sponsor:

McGill University

Code:

NCT00764972

Conditions

Metastatic Breast Cancer

Eligibility Criteria

Sex: Female

Age: 19 - 65

Healthy Volunteers: Not accepted

Interventions

Sorafenib and Vinorelbine

Study Details

Brief summary:

This is a phase IB/II trial of sorafenib, a new tyrosine kinase inhibition of multiple genes that is active against renal cancer, plus vinorelbine, a chemotherapy agent active in breast cancer.

The investigators are combining these 2 drugs in order to determine if the investigators can increase the activity of vinorelbine in metastatic breast cancer patients.

Patients with measurable metastatic breast cancer without previous chemotherapy for metastatic disease are eligible for the protocol. They will be treated with 2 different dose levels of sorafenib in order to determine the most tolerable dose.

Conditions

Metastatic Breast Cancer

Study ID

NCT00764972

Start date

Oct, 2007

Status verified date

Oct, 2008

Completion date

Dec, 2011

Anticipated

Primary completion date

Dec, 2010

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 19 - 65

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Women affected by histologically proven metastatic breast cancer.
  • Tumor not susceptible to therapy with trastuzumab, defined as FISH negative for HER-2 amplification or immunohistochemistry 0-1+ for HER-2 expression.
  • Female, age ≥ 18.
  • Documented measurable disease by appropriate radiologic imaging according to RECIST criteria (see Appendix E). Lesions in previously irradiated areas are not considered measurable disease, unless progression has been documented post-radiation.
  • ECOG performance status 0-1 (see Appendix B)
  • Life expectancy > 6 months.
  • Adequate bone marrow function, as indicated by:

  • Hemoglobin ≥ 90 g/L
  • Neutrophils ≥ 1.5 x 109/L
  • Platelets ≥ 100 x 109/L
  • Adequate renal function, as indicated by serum creatinine ≤1.5 times the upper limit of normal and/or Creatinine Clearance calculated as >50% lower normal limit, or estimated as ≥ 50 ml/min (Appendix C).
  • Adequate liver function, as indicated by:

  • bilirubin ≤ 1.5 times upper normal limit;
  • AST and ALT ≤ 2 times upper normal limit.
  • Left ventricular ejection fraction (LVEF) ≥50% as measured by either multigated acquisition (MUGA) scan or echocardiogram (ECHO).
  • No therapy for breast cancer in the 4 weeks preceding the therapy start.
  • Women of childbearing potential must be using adequate contraception and have a negative pregnancy test at the time of enrollment.
  • Patient able to understand and give written informed consent.

Exclusion Criteria:

  • Patients with locally advanced breast cancer or stage IIIb only.
  • Presence of only non-measurable disease.
  • Previous (neo)adjuvant chemotherapy with vinorelbine.
  • Any previous anti-angiogenic therapy.
  • Any previous chemotherapy for metastatic breast cancer. Previous hormonal treatments or radiotherapy for metastatic disease are allowed.
  • Radiotherapy, chemotherapy or hormonal therapy for breast cancer in the last 4 weeks prior to starting the study treatment.
  • Major surgery within 4 weeks of first study treatment, or minor surgery (including placement of an access device) within 7 days of therapy start.
  • Presence of life-threatening disease or central nervous system localizations.
  • Evidence of HER-2 positive breast cancer, defined as FISH-positive for amplification or score 3+ by immunohistochemistry.
  • Any other possibly active primary tumor, except basal cell carcinoma of the skin, or carcinoma in situ of the cervix.
  • Clinically significant hepatic disease with respect to hepatitis B, hepatitis C, cirrhosis or other liver diseases.
  • Uncontrolled bacterial, viral or fungal infection.
  • Previous history of ischemic disease.
  • Patients with previous history of thrombo-embolic events, or with documented risk factors for thrombotic disease other than cancer.
  • History of gross hemorrhage within the past 6 months (e.g., hemoptysis or hematuria requiring medical intervention).
  • Uncontrolled hypertension.
  • Other serious medical conditions, such as uncontrolled cardiac disease, severe pulmonary disease, uncontrolled diabetes.
  • Patient exhibiting confusion or disorientation.
  • Any condition (medical, social, psychological, geographical) that would prevent adequate follow-up.
  • Patient is pregnant, or is breast-feeding, or is unwilling to use adequate contraception.
  • Failure to give informed consent.

Study Design

Enrollment

36 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Sorafenib and Vinorelbine

Interventions

Sorafenib and Vinorelbine

vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);

sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe.

Primary outcome measure

  • Confirmed complete response (CR) or partial response (PR), defined according to RECIST criteria, persisting 4 weeks after the initial documentation. [ Time Frame: undefined ]

Central Contacts and Locations

Central contacts

Lawrence Panasci

514-340-8248lpanasci@hotmail.com

Cristiano Ferrario

514-340-8248cristianoferrario@gmail.com

Locations

Jewish General Hospital

Recruiting

Montreal, Quebec, Canada, H3T 1E2

Contacts

Lawrence Panasci

514-340-8248lpanasci@hotmail.com

Cristiano Ferrario

514-340-8248cristianoferrario@gmail.com

Principal Investigator:

Lawrence Panasci

More Information

Sponsor

McGill University

Last update posted

Oct 21, 2008

Last verified

Oct, 2008

Keywords

  • To evaluate the use of sorafenib added to vinorelbine chemotherapy, to find out which are the doses of two drugs can be safely combined

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by McGill University on 2008-10-21.